Type 2 Diabetes Trial, Recruiting (NCT05008276)

Type 2 Diabetes Trial, Recruiting NCT05008276 Sponsor: Petter Bjornstad Condition: Type 2 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT05008276 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 2 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People in the high-risk group whose HbA1c blood sugar marker is 6.0% or higher and who have not yet been treated
People in the high-risk group whose BMI (body mass index) falls at or above the 85th percentile for their age group
People in the control group whose HbA1c blood sugar marker is 5.6% or lower (considered normal)
People who have tested negative for Type 1 diabetes antibodies

Who may not be able to join:

People who have a history of chronic kidney disease or a recent serious kidney injury
People who have a metabolic condition that makes fasting unsafe for them
People who have an allergy to iodine or penicillin
People who are pregnant
People who have a blood clotting disorder known as thrombophilia
People for whom MRI scans are not safe or suitable (confirm with trial site)
People who are currently using hormone therapy

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Petter Bjornstad, MD, University of Washington - Medicine Diabetes Institute

Phone: (206) 616 3543

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05008276

Sponsor: Petter Bjornstad

Phase: Not Applicable

Status: Recruiting

Condition: Type 2 Diabetes

Trial contact: (206) 616 3543

More information: https://clinicaltrials.gov/study/NCT05008276

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People in the high-risk group whose HbA1c blood sugar marker is 6.0% or higher and who have not yet been treated
People in the high-risk group whose BMI (body mass index) falls at or above the 85th percentile for their age group
People in the control group whose HbA1c blood sugar marker is 5.6% or lower (considered normal)
People who have tested negative for Type 1 diabetes antibodies

Who may not be able to join:

People who have a history of chronic kidney disease or a recent serious kidney injury
People who have a metabolic condition that makes fasting unsafe for them
People who have an allergy to iodine or penicillin
People who are pregnant
People who have a blood clotting disorder known as thrombophilia
People for whom MRI scans are not safe or suitable (confirm with trial site)
People who are currently using hormone therapy

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Petter Bjornstad

Registry

ClinicalTrials.gov

Start date

27 September 2021

Est. completion

1 December 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Effective renal plasma flow (ERPF); Glomerular Filtration Rate (GFR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov